New non-opioid pain reliever approved by US Health Agency
A new type of non-opioid painkillers have been approved by the American Food and Drug Administration (FDA) for the purpose of treating short-term pain in adults.
Drug Sujatrigin, known by its brand magazines, works by targeting pain signals before reaching the brain.
Its manufacturer Vertex Pharmaceuticals stated that it enables to provide effective relief to moderate to severe pain without “drug addiction of opioids”.
The US has been struggling with a pain reliever-addition crisis for years. In 2017, US President Trump called it a “national shame” and declared a public health emergency.
The FDA stated that clinical trials showed that Jaanavaks reduced the pain after surgery, and its approval called “an important public health milestone in acute pain management”.
According to the US Center for Disease Control and Prevention (CDC), every year thousands of Americans die from the use of opioids, with 82,000 Opioid-Shail overdose deaths in 2022.
Now in his second term, President Trump has He said that he would import from Canada and Mexico with 25% limit taxes To address a large amount of fentinyl – a powerful synthetic opioid – crossing in the country.
The President has also threatened to impose tariffs on China, citing the country’s Phentenele exports as a reason.
Drugs Work by stimulating opioid receptors in the brain, blocking pain signals,
During the process, the brain also causes floods, excitement feelings with neurotransmitter dopamine and activates the reward system of the brain.
This makes opioids extremely intoxicated. Vertex estimates that about 10% of patients with acute pain are initially treated with an opioid, which will use opioid for a long time.
But Journavx works in a different way, By blocking pain signals before reaching the brain.
Vartex says that this drug is the first in a new section of the pain drug approved in more than 20 years.
Its Chief Executive Officer Reshma Kewala Mani called the approval “a historic milestone for 80 million people in the US, which is prescribed a drug for moderate-to-serious pain every year”.
Journavx will cost $ 15.50 (£ 12.50) per capsule, The company said, Adding it is not yet known whether the drug is “safe and effective in children”.
